Is SLNO or FEMY more profitable?

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Soleno Therapeutics 33.70% 22.85% 18.25% Femasys -521.97% -258.08% -73.72%

Is FEMY or SRTS more profitable?

Sensus Healthcare has a net margin of -34.50% compared to Femasys' net margin of -521.97%. Sensus Healthcare's return on equity of -15.79% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Sensus Healthcare -34.50% -15.79% -14.02%

Do analysts prefer QTI or FEMY?

Femasys has a consensus price target of $106.67, suggesting a potential upside of 2,457.95%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than QT Imaging. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QT Imaging 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is QTI or FEMY more profitable?

QT Imaging has a net margin of -58.93% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat QT Imaging's return on equity. Company Net Margins Return on Equity Return on Assets QT Imaging -58.93% -4,220.38% -51.77% Femasys -521.97% -258.08% -73.72%

Is FEMY or DRIO more profitable?

DarioHealth has a net margin of -192.23% compared to Femasys' net margin of -521.97%. DarioHealth's return on equity of -60.52% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% DarioHealth -192.23% -60.52% -37.08%

Do analysts prefer FEMY or BDMD?

Femasys presently has a consensus target price of $106.67, indicating a potential upside of 2,457.95%. Given Femasys' stronger consensus rating and higher possible upside, equities research analysts clearly believe Femasys is more favorable than Baird Medical Investment. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, FEMY or BDMD?

Baird Medical Investment has higher revenue and earnings than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 5.50 -$18.63M -$5.40 N/A Baird Medical Investment $22.54M 2.15 N/A N/A N/A

Femasys (FEMY) Competitors

$4.17 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.18 +0.01 (+0.36%)

As of 07/2/2026 06:54 PM Eastern

Compare

FEMY vs. SLNO, SRTS, QTI, DRIO, and BDMD

Should you buy Femasys stock or one of its competitors? MarketBeat compares Femasys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Femasys include Soleno Therapeutics (SLNO), Sensus Healthcare (SRTS), QT Imaging (QTI), DarioHealth (DRIO), and Baird Medical Investment (BDMD). These companies are all part of the "medical equipment" industry.

How does Femasys compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Soleno Therapeutics presently has a consensus price target of $76.67, indicating a potential upside of 44.63%. Femasys has a consensus price target of $106.67, indicating a potential upside of 2,457.95%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Soleno Therapeutics has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95
Femasys	$2.29M	5.50	-$18.63M	-$5.40	N/A

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 7.8% of Femasys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Femasys	-521.97%	-258.08%	-73.72%

Soleno Therapeutics has a beta of -2.22, meaning that its stock price is 322% less volatile than the broader market. Comparatively, Femasys has a beta of -2.13, meaning that its stock price is 313% less volatile than the broader market.

In the previous week, Soleno Therapeutics' average media sentiment score of 0.94 beat Femasys' score of 0.00 indicating that Soleno Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Soleno Therapeutics	Positive
Femasys	Neutral

Summary

Soleno Therapeutics beats Femasys on 10 of the 14 factors compared between the two stocks.

How does Femasys compare to Sensus Healthcare?

Femasys (NASDAQ:FEMY) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

65.3% of Femasys shares are owned by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are owned by institutional investors. 7.8% of Femasys shares are owned by company insiders. Comparatively, 10.2% of Sensus Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Femasys presently has a consensus target price of $106.67, suggesting a potential upside of 2,457.95%. Sensus Healthcare has a consensus target price of $6.88, suggesting a potential upside of 123.94%. Given Femasys' higher probable upside, equities research analysts plainly believe Femasys is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Sensus Healthcare has a net margin of -34.50% compared to Femasys' net margin of -521.97%. Sensus Healthcare's return on equity of -15.79% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

In the previous week, Femasys' average media sentiment score of 0.00 equaled Sensus Healthcare'saverage media sentiment score.

Company	Overall Sentiment
Femasys	Neutral
Sensus Healthcare	Neutral

Sensus Healthcare has higher revenue and earnings than Femasys. Sensus Healthcare is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	5.50	-$18.63M	-$5.40	N/A
Sensus Healthcare	$22.53M	2.24	-$7.72M	-$0.47	N/A

Femasys has a beta of -2.13, suggesting that its stock price is 313% less volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Summary

Sensus Healthcare beats Femasys on 10 of the 14 factors compared between the two stocks.

How does Femasys compare to QT Imaging?

QT Imaging (NASDAQ:QTI) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, QT Imaging had 1 more articles in the media than Femasys. MarketBeat recorded 1 mentions for QT Imaging and 0 mentions for Femasys. QT Imaging's average media sentiment score of 1.34 beat Femasys' score of 0.00 indicating that QT Imaging is being referred to more favorably in the media.

Company	Overall Sentiment
QT Imaging	Positive
Femasys	Neutral

Femasys has a consensus price target of $106.67, suggesting a potential upside of 2,457.95%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than QT Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QT Imaging	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Femasys has lower revenue, but higher earnings than QT Imaging. QT Imaging is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QT Imaging	$22.66M	2.15	-$21.08M	-$1.24	N/A
Femasys	$2.29M	5.50	-$18.63M	-$5.40	N/A

QT Imaging has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market. Comparatively, Femasys has a beta of -2.13, suggesting that its share price is 313% less volatile than the broader market.

24.2% of QT Imaging shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 28.8% of QT Imaging shares are owned by company insiders. Comparatively, 7.8% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

QT Imaging has a net margin of -58.93% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat QT Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QT Imaging	-58.93%	-4,220.38%	-51.77%
Femasys	-521.97%	-258.08%	-73.72%

Summary

QT Imaging and Femasys tied by winning 8 of the 16 factors compared between the two stocks.

How does Femasys compare to DarioHealth?

Femasys (NASDAQ:FEMY) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

DarioHealth has a net margin of -192.23% compared to Femasys' net margin of -521.97%. DarioHealth's return on equity of -60.52% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
DarioHealth	-192.23%	-60.52%	-37.08%

65.3% of Femasys shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Comparatively, 3.5% of DarioHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Femasys has a beta of -2.13, indicating that its share price is 313% less volatile than the broader market. Comparatively, DarioHealth has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Femasys has higher earnings, but lower revenue than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	5.50	-$18.63M	-$5.40	N/A
DarioHealth	$22.36M	2.38	-$41.71M	-$8.88	N/A

Femasys currently has a consensus price target of $106.67, indicating a potential upside of 2,457.95%. DarioHealth has a consensus price target of $10.50, indicating a potential upside of 44.23%. Given Femasys' stronger consensus rating and higher probable upside, research analysts clearly believe Femasys is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, DarioHealth had 5 more articles in the media than Femasys. MarketBeat recorded 5 mentions for DarioHealth and 0 mentions for Femasys. DarioHealth's average media sentiment score of 0.20 beat Femasys' score of 0.00 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Overall Sentiment
Femasys	Neutral
DarioHealth	Neutral

Summary

Femasys beats DarioHealth on 9 of the 16 factors compared between the two stocks.

How does Femasys compare to Baird Medical Investment?

Femasys (NASDAQ:FEMY) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Femasys has a beta of -2.13, indicating that its stock price is 313% less volatile than the broader market. Comparatively, Baird Medical Investment has a beta of -1.17, indicating that its stock price is 217% less volatile than the broader market.

In the previous week, Baird Medical Investment had 1 more articles in the media than Femasys. MarketBeat recorded 1 mentions for Baird Medical Investment and 0 mentions for Femasys. Femasys' average media sentiment score of 0.00 equaled Baird Medical Investment'saverage media sentiment score.

Company	Overall Sentiment
Femasys	Neutral
Baird Medical Investment	Neutral

Baird Medical Investment has higher revenue and earnings than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	5.50	-$18.63M	-$5.40	N/A
Baird Medical Investment	$22.54M	2.15	N/A	N/A	N/A

Femasys presently has a consensus target price of $106.67, indicating a potential upside of 2,457.95%. Given Femasys' stronger consensus rating and higher possible upside, equities research analysts clearly believe Femasys is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Baird Medical Investment	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Baird Medical Investment has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Baird Medical Investment's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Baird Medical Investment	N/A	N/A	N/A

65.3% of Femasys shares are held by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are held by institutional investors. 7.8% of Femasys shares are held by company insiders. Comparatively, 78.9% of Baird Medical Investment shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Baird Medical Investment beats Femasys on 7 of the 12 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEMY vs. The Competition

Export

Metric	Femasys	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.59M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.77	21.61	28.02	24.70
Price / Sales	5.50	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	2.07	8.66	10.96	6.46
Net Income	-$18.63M	$23.81M	$3.57B	$337.01M
7 Day Performance	10.32%	3.39%	2.12%	1.69%
1 Month Performance	-31.95%	10.81%	5.25%	3.81%
1 Year Performance	-77.68%	62.61%	33.29%	23.90%

Femasys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEMY Femasys	1.9724 of 5 stars	$4.17 flat	$106.67 +2,458.0%	-77.7%	$12.59M	$2.29M	N/A	30	Gap Up
SLNO Soleno Therapeutics	N/A	$53.01 flat	$76.67 +44.6%	N/A	$2.76B	$285.01M	29.95	30
SRTS Sensus Healthcare	3.404 of 5 stars	$3.02 -1.3%	$6.88 +127.6%	-36.8%	$49.71M	$27.48M	N/A	40	Positive News
QTI QT Imaging	1.548 of 5 stars	$4.07 +0.7%	N/A	+185.6%	$49.00M	$18.92M	N/A	N/A	Positive News
DRIO DarioHealth	2.2231 of 5 stars	$6.60 -2.9%	$10.50 +59.1%	-48.1%	$48.25M	$22.36M	N/A	200	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEMY) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Femasys (FEMY) Competitors

FEMY vs. SLNO, SRTS, QTI, DRIO, and BDMD

How does Femasys compare to Soleno Therapeutics?

Summary

How does Femasys compare to Sensus Healthcare?

Summary

How does Femasys compare to QT Imaging?

Summary

How does Femasys compare to DarioHealth?

Summary

How does Femasys compare to Baird Medical Investment?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Femasys (FEMY) Competitors

FEMY vs. SLNO, SRTS, QTI, DRIO, and BDMD

How does Femasys compare to Soleno Therapeutics?

Do analysts rate SLNO or FEMY?

Which has higher earnings and valuation, SLNO or FEMY?

Do insiders and institutionals have more ownership in SLNO or FEMY?

Is SLNO or FEMY more profitable?

Which has more volatility & risk, SLNO or FEMY?

Does the media prefer SLNO or FEMY?

Summary

How does Femasys compare to Sensus Healthcare?

Do insiders & institutionals hold more shares of FEMY or SRTS?

Do analysts rate FEMY or SRTS?

Is FEMY or SRTS more profitable?

Does the media favor FEMY or SRTS?

Which has stronger valuation & earnings, FEMY or SRTS?

Which has more risk & volatility, FEMY or SRTS?

Summary

How does Femasys compare to QT Imaging?

Does the media refer more to QTI or FEMY?

Do analysts prefer QTI or FEMY?

Which has stronger earnings & valuation, QTI or FEMY?

Which has more volatility & risk, QTI or FEMY?

Do insiders & institutionals have more ownership in QTI or FEMY?

Is QTI or FEMY more profitable?

Summary

How does Femasys compare to DarioHealth?

Is FEMY or DRIO more profitable?

Do institutionals & insiders believe in FEMY or DRIO?

Which has more volatility and risk, FEMY or DRIO?

Which has stronger earnings & valuation, FEMY or DRIO?

Do analysts recommend FEMY or DRIO?

Does the media prefer FEMY or DRIO?

Summary

How does Femasys compare to Baird Medical Investment?

Which has more volatility and risk, FEMY or BDMD?

Does the media prefer FEMY or BDMD?

Which has better earnings and valuation, FEMY or BDMD?

Do analysts prefer FEMY or BDMD?

Is FEMY or BDMD more profitable?

Do institutionals and insiders believe in FEMY or BDMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools